Novo Nordisk files for FDA approval of Wegovy 7.2 mg

Novo Nordisk submitted an application to the U.S. Food and Drug Administration on November 26, 2025, seeking approval of a higher-dose version of Wegovy, semaglutide 7.2 mg, for chronic weight management in adults with obesity ^[1]. The filing is being reviewed under the FDA's Commissioner's National Priority Voucher pilot program, which is meant to speed up review of products addressing major national health priorities. Under that program, the company expects a decision within one to two months after the FDA formally accepts the filing ^[1].

The application is based on the STEP UP trial, a 72-week, placebo-controlled study of 1,407 adults with obesity (BMI of 30 or higher) who did not have diabetes ^[1]. Participants started at an average body weight of 249 pounds. Among people who stuck with treatment as directed, those on semaglutide 7.2 mg lost an average of 20.7% of their body weight, compared with 17.5% for people on the current 2.4 mg dose and 2.4% for placebo ^[1]. About 33.2% of people on the 7.2 mg dose lost 25% or more of their body weight, versus 16.7% on 2.4 mg and none on placebo ^[1].

When the analysis included everyone who started the trial, even those who stopped treatment early, the numbers were lower but still favored the higher dose: 18.7% weight loss for 7.2 mg, 15.6% for 2.4 mg, and 3.9% for placebo ^[1]. About 90.7% of people on 7.2 mg lost at least 5% of their body weight, close to the 89.9% seen with 2.4 mg and far above the 36.8% seen with placebo ^[1].

Gastrointestinal side effects, along with a nerve-related symptom called dysaesthesia, were reported more often with the 7.2 mg dose than with 2.4 mg or placebo ^[1]. Serious adverse events, however, were reported by 6.8% of people on 7.2 mg, compared with 10.9% on 2.4 mg and 5.5% on placebo ^[1]. The company's release does not explain why the serious-event rate was lower on the higher dose, and that detail is not yet clear from the available data.

Why it matters for patients

For people already taking Wegovy at the current maximum dose of 2.4 mg, a 7.2 mg option could offer a path to more weight loss without switching medications, if it is approved ^[1]. The trial data suggest a meaningful jump in average results, from about 17.5% to 20.7% weight loss among people who stayed on treatment as prescribed ^[1]. But the trial also excluded people with diabetes, so it is not yet known how the higher dose would perform in that group ^[1].

More gastrointestinal side effects and dysaesthesia at the higher dose mean some patients may find 7.2 mg harder to tolerate than the current dose, even though overall serious adverse event rates were not higher in this trial ^[1]. Anyone considering a dose change would need to weigh potential added benefit against potential added side effects, a decision that depends on individual health history and is not addressed by this filing alone.

What happens next

The FDA has not yet said whether it has formally accepted the application; once it does, a decision is expected within one to two months under the priority voucher program ^[1]. In the European Union, the same higher dose is under review by the European Medicines Agency, with a decision expected in the first quarter of 2026 ^[1]. The dose is also under review in the United Kingdom and several other countries, according to Novo Nordisk ^[1]. Until regulators complete these reviews, semaglutide 7.2 mg is not available for prescription in the United States.